Sign-up for our monthly newsletter!

Sign-up for the M&A Perspective Newsletter!

Sign-up for the Arbitration Case Alert Newsletter!

 
Life Sciences

Protecting Your Competitive Edge

Schellenberg Wittmer’s Life Sciences Group is recognized as a leading practice for litigation, arbitration, transactional work and regulatory matters in the fields of Life Sciences.

We advise and represent Life Sciences clients from a variety of sectors, including pharma, biotech, medical devices and food.

„outstanding arbitration and litigation practice advising both plaintiffs and respondents in patent litigation.“

Chambers Europe

Contact

Philipp Groz
Partner Zurich
Partner
Philipp Groz
Partner Zurich
Pascal Hubli
Partner Zurich
David Mamane
Partner Zurich
Roland Mathys
Partner Zurich
Dr. Oliver Triebold
Partner Zurich
Full Team
Philipp Groz
Partner Zurich
Pascal Hubli
Partner Zurich
David Mamane
Partner Zurich
Roland Mathys
Partner Zurich
Dr. Oliver Triebold
Partner Zurich
Dr. Samuel Hagenstein-Jost
Counsel Zurich
Teresa Rudolph
Associate Zurich

Expertise

Litigation/Arbitration

We represent clients in litigation, arbitration and mediation proceedings concerning a broad range of issues, including:

  • Entitlement, validity and infringement of patents, SPCs and other IP rights;
  • Disputes arising out of licensing, non-disclosure, R&D, technology transfer, manufacturing, distribution and clinical trials agreements;
  • Product liability and product recall matters.

Transactions

  • R&D, licensing and development, IP and technology transfer, manufacturing and distribution agreements;
  • Joint ventures;
  • Mergers & Acquisitions;
  • Venture capital and private equity.

Advice and Regulatory

  • Clinical trial agreements;
  • Procedures before Swissmedic, health authorities and administrative courts;
  • Pharmaceutical advertising;
  • Compliance and investigations;
  • E-health, medical software and data protection;
  • Competition law.

Our experience includes:

  • Advised Panasonic Healthcare as Swiss counsel in its acquisition of the Diabetes Care business from Bayer (total transaction value approx. EUR 1 billion);
  • Represented U.S. pharmaceutical company in a USD 210 million arbitration against German pharmaceutical company concerning non-compliance with GMP, supply of deficient drug product;
  • Assisted Swiss listed pharmaceutical company in negotiating and drafting major in-licensing deal;
  • Advised Cardinal Health as Swiss counsel in the acquisition of Johnson & Johnson’s Cordis business, a global leader in cardiology and endovascular devices;
  • Represented major Swiss medical device manufacturer in patent litigation before Swiss Federal Patent Court;
  • Representation of Quark Pharmaceuticals in an ICC arbitration seated in Zurich arising out of a patent licensing agreement;
  • Representation of global provider of drug delivery technology solutions in complex mediation concerning a patent and know-how licensing and an equipment purchasing agreement for a novel drug delivery technology.

Deals & Cases

Schellenberg Wittmer advises Santhera Pharmaceuticals in exclusive License Agreement with Polyphor

Schellenberg Wittmer advises Cardinal Health in acquisition of Medtronic division

Awards and Recognitions

The group and leading practitioners are highly recognized amongst leading law firms across international directories and publications:

  • Chambers Europe in Life Sciences
  • Legal 500 in Life Sciences
  • IP Stars
  • The World’s Leading Patent Professionals